MAQS advised Oblique Therapeutics on the deal.Oblique Therapeutics AB (publ) completed a rights issue of approximately SEK 53.2 million. Oblique Therapeutics is a privately held Swedish…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Federica Tiefenthaler
…
This content is for Standard 1 Year members only. LoginJoin Now